Prosecution Insights
Last updated: August 18, 2026

Examiner: BOECKELMAN, JACOB A

Tech Center 1600 • Art Units: 1628 1655

This examiner grants 36% of resolved cases

Performance Statistics

36.1%
Allow Rate
-23.9% vs TC avg
356
Total Applications
+46.1%
Interview Lift
1136
Avg Prosecution Days
Based on 244 resolved cases, 2023–2026

Rejection Statute Breakdown

13.9%
§101 Eligibility
13.2%
§102 Novelty
52.4%
§103 Obviousness
15.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18795597 PEST CONTROL COMPOSITIONS CONTAINED IN PLASTIC CONTAINERS Non-Final OA The Procter & Gamble Company
18702598 COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIAL TISSUE Non-Final OA MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
18697375 INJECTABLE BIOMATERIAL FOR DYSPHAGIA Non-Final OA The Regents of the University of California
18504646 COMPOSITIONS INCLUDING FILAMENTOUS FUNGAL BIOMASS AND CULTURED ANIMAL CELLS, AND METHODS OF FORMING AND USING Final Rejection The Regents of the University of California
17795604 COMPOSITIONS AND METHODS FOR COATING BONE GRAFTS Non-Final OA UNIVERSITY OF ROCHESTER
17996649 COMPOSITION COMPRISING FIBRE AND MULBERRY Non-Final OA SOCIETE DES PRODUITS NESTLE S.A.
17596513 USE OF WHEY PROTEIN MICELLES FOR CONTROLLING POSTPRANDIAL GLUCOSE RESPONSE Final Rejection SOCIETE DES PRODUITS NESTLE S.A.
17920699 BOWEL MOVEMENT IMPROVING COMPOSITION COMPRISING TENEBRIONIDAE LARVA EXTRACT Non-Final OA CJ CHEILJEDANG CORPORATION
17782914 COMPOSITIONS AND METHODS FOR PREVENTING RECURRENCE OF CANCER Final Rejection YALE UNIVERSITY
17783276 BACTERIA-ASSOCIATED VOLATILE ORGANIC COMPOUNDS Final Rejection Ramot at Tel-Aviv University Ltd.
18333934 Microspheres Containing Decellularized Donor Tissue and Their Use in Fabricating Polymeric Structures Non-Final OA CHILDREN'S HOSPITAL MEDICAL CENTER
18368040 ANTIMICROBIAL AGENTS DERIVED FROM BACILLUS Final Rejection The state of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization
18285648 TREATMENT OF CANCER WITH NK CELLS AND AN EGFR TARGETED ANTIBODY Non-Final OA GC CELL CORPORATION

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month